BMS Opens Mumbai GCC to Scale AI and Data Analytics
Global drugmaker Bristol Myers Squibb (BMS) is making a big AI bet on India. The company has opened a Global Capability Centre (GCC) in Mumbai to scale its AI and data analytics work. A GCC is an in-house hub a global company sets up in another country to run key tasks like technology, data, and analytics. BMS wants this centre to support its teams worldwide. The move builds on the company’s growing India base of over 3,000 professionals.
BMS is one of the world’s largest biopharma firms. “Biopharma” means companies that make medicines, often using biology and advanced science. BMS is known for cancer, blood, and heart drugs. Now it is using India’s talent to speed up how it brings those drugs to doctors and patients. The new Mumbai centre is central to that plan.
What is a GCC, and why Mumbai?
A Global Capability Centre is an offshore office that does high-value work for the parent company. It is not a simple call centre. These centres handle data analytics, technology, AI, and research. India has become the world’s top spot for GCCs because of its deep tech talent and lower costs. BMS is now joining the many global firms expanding their GCC presence here.
The Mumbai centre will support BMS teams across the globe. Its focus areas include data analytics, technology, AI, and client and operational services. The aim is clear: use data and AI to make the whole business faster and smarter. Leaders have stressed that this is real innovation work, not just back-office support.
The Mosaic AI content hub
Alongside the GCC, BMS launched an AI tool called Mosaic in Mumbai, built with partner Accenture. Mosaic is a generative AI platform. Generative AI is software that creates new content, like text or designs, on demand. Mosaic spots what doctors need in real time. Then it quickly builds personalised, rule-following medical and marketing content for them.
The goal is speed. BMS says the tool can cut the time to update doctors on new trial data from months to just weeks. That is a huge gain in a field where getting the latest science to physicians fast can help patients sooner. Mosaic sits within a broader AI push worth more than $100 million across BMS’s commercial work, with reports placing the figure near $130 million.
Key facts
| Item | Detail |
|---|---|
| Company | Bristol Myers Squibb (BMS) |
| New centre | Global Capability Centre (GCC), Mumbai |
| Focus | AI, data analytics, technology, operations |
| India talent base | Over 3,000 professionals |
| AI investment | $100 million+ (reported near $130 million) |
| AI tool | Mosaic, built with Accenture |
| Mosaic benefit | Doctor updates cut from months to weeks |
| Therapy focus | Oncology, hematology, cardiology |
What leaders are saying
The launch drew senior leaders. Mosaic was inaugurated by Adam Lenkowsky, Chief Commercialization Officer at BMS, and Ndidi Oteh, Global CEO of Accenture Song. Lenkowsky said the company has been growing rapidly in India, largely in cancer treatments. Anvita Karara, who leads AI Commercial Transformation, made a key point. She said the Mumbai team is leading AI work — making clear this is true innovation, not just a support office.
BMS has had a presence in India for over 20 years. Its partnership with Accenture spans more than 25 years. The India work is set to expand further, with the AI model reportedly rolling out to Germany and Japan in 2026.
FAQ
What does BMS stand for?
BMS stands for Bristol Myers Squibb. It is a large global biopharma company that makes medicines for cancer, blood disorders, and heart conditions.
What is a Global Capability Centre (GCC)?
A GCC is an in-house centre a global company opens in another country. It runs important work like data, technology, AI, and analytics for the whole company, not just the local market.
What does the Mosaic tool do?
Mosaic is a generative AI hub. It finds what doctors need and quickly builds personalised, compliant content for them. This can cut update times from months to weeks.
Why it matters (especially for India and founders)
This is a strong vote of confidence in India’s AI talent. A major global drugmaker is choosing Mumbai to lead its AI work, not just to cut costs. That lifts India up the value chain — from doing routine tasks to driving real innovation. It also means more high-skill jobs in AI and data analytics for Indians.
For Indian founders and job seekers, the trend is clear. Global firms now run their smartest projects from India. The same shift is visible across sectors. A homegrown startup is turning financial advisors into AI-powered wealth coaches. And large Indian platforms like IndiaMART are running giant AI systems too. India is fast becoming a global AI hub.
The takeaway
BMS opening a Mumbai GCC for AI and data analytics is more than one company’s move. It signals where global biopharma is heading: India-led, AI-driven, and faster. With a 3,000-strong India team and a $100 million-plus AI push, BMS is betting that the future of medicine marketing is built in India. Expect more global giants to follow.
Sources
- Analytics India Magazine — BMS Opens Mumbai GCC to Scale AI, Data Analytics Capabilities
- Digital Health News — Bristol Myers Squibb, Accenture launch AI-powered content hub ‘Mosaic’ in Mumbai
- India Pharma Outlook — Bristol Myers Squibb Bets on India, AI to Fuel Next Growth Phase
Related coverage
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
